Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes I agree, but make no mistake I actually enjoy very much Sojo's technical analysis which is to the point and off the chart. After all he/she is not chart predicting appl or tsla.
So I enjoy his/her brilliant TA with a lightened mood.
I thought I am a person who doesn't care about a few pennies of difference, when I am in accumulation mood for a company like NWBIO which I think will change the world of cancer treatment.
I thank Linda for painstakingly making sure the first step is right and to the maximal effect: to approve the concept of DCVax-L in treating cancers with positive trial data for GBM.
After that, I have not doubt things will move in a lighting speed.
It's useless to guess price movement. A major seller or buyer would change all patterns right away on a daily basis, involving measly hundreds of thousand shares.
The shares have been accumulated, but it seems not in a big way. there have been no forms 4, and it seems there would not be any before data announcement or any other major news.
Smith is truly "independent" analyst because he has no collaborators in the support of each and every his analytic report, even not a single son/daughter/grandson/daughter of his are buying a single shares at the release of his report, let alone any collaborating funds.
So in short term, he is nobody in terms of share price movement, and if he by chance draws some retails into buying nwbo shares, it's easy for manipulators to quell quickly.
MMs want everybody to think the price in this range ($1.5-$1.6) is reasonable as of now.
It all sounds a little depress for anyone who cares about every day's price movement, but for those who set their sights on the big prize, it's actually good opportunities to accumulate.
Everybody is now waiting and something will be revealing, either from quarterly, annually, or share holder meeting, if not the big one everybody has been waiting since early October.
As I said before we have been well past pure TLD stage, when news comes, it will be plural in a short span and much more significant, despite TLD still the first to come.
I suspect accumulation is indeed going on or has been going on for a while. Definitely somebody (a market maker or two) may involve. They don't want to report some of their trades for a reason during trading hours and preferred to lump them up after hours in the form of a T-trade. MMs may not want to give signal prematurely before they get it done. It is legal though under the FINRA rules of the OTC Markets as long as MMs report all trades of the day on that day either when it happens or after it happens.
Guess it's clear to everybody the trial will readily meet its primary endpoint and some if not all secondary endpoints, with long-term survival data unprecedented or unheard of.
It becomes increasingly hard for MMs to operate by stealth as time goes by.
GL
IMHO, definitely positive despite somebody may spin negatively otherwise. My simple interpretation of the quote from Bill Malloy interview with LL below is 1) it's impossible to design a trial without giving chance to patients the real shots after their GBMs progress [it's true in the past and it's true today. FDA has to adapt to it because the sponsors designing and running the trial have no way to change this situation;] 2)FDA has to catch up with the nature of immunotherapy for accepting appropriate measures for its efficacy. As a result, today we know FDA has exactly caught up and come up with this guidance:
Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products Guidance for Industry (https://www.fda.gov/media/133660/download)
And specifically, NWBIO has received Regulatory Agencies' acceptance of NWBIO's adapted reordered endpoints (https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001977-13/GB, and https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001977-13/DE)
"Q: Can you explain more about the difficulties in designing the trials to do what’s best for the patient?
A: For instance, I’ll just take what happened with the DCVax. You really want to get clean data. We’ve never allowed for patients to get the vaccine once they failed, because they will. You enrolled in the trial. You had a recurrence, and now you’ll have to try something else.
I could tell you patients are fighting to get the vaccine. And even if you tell them, “Well, there’s no proof that this works. This is the whole reason we have to do the trial. I can’t tell you that there’s any benefit.” But I guess the counterargument that I hear quite often is, “well, the side-effects aren’t bad.” And they’re not. So, it’s like, “Well, if it’s not going to hurt me why can’t I have it? Why can’t I try it?”
Because of that it’s hard to prove something based on what the FDA requirements are without being a little cold-hearted and saying, “Well, no, you’re not allowed to try that.”
So, a part of it is having the FDA think a little bit differently about what constitutes approval. On the converse, like the Optune device, that Novocure device, is FDA-approved. But I must say a lot of patients are like, “Well, I don’t really like it.” And I think on the physician side, we just don’t understand how it works and there are a lot of problems with the clinical trial design.
There was no true placebo arm, but they did design it in a way that met the FDA checkboxes. So, it was approved, but a lot of us don’t really believe that it works. I think it’s one of these things where if your ultimate goal is to cure GBM, it’s hard to reconcile all these different factors; the regulatory factors, the financial factors, as well as the science and the biology of the tumor itself, which is very complex.
Q: Got it. Sounds like we have our work cut out for us.
A: Yeah, but if your smart people can figure this out, I think it could be done. It’s been done in other fields, but I think it just takes a different way of thinking about it, and it’s not the “Eureka!” moment of, “oh, I discovered something in the lab. I’m going to take it to clinical trial, launch my startup company, and charge ABM.”"
Maybe he just wanted to signal to you to sell and hoped you would no longer bombard him via email/phone constantly.
Yes I have added about 100,000 shares to my wife's accounts;
yes I am a believer of big prize in the horizon, regardless what that term "in coming months" mean; for me it means nothing but accumulation. Not even a single one form 4 has reported recently;
yes, I don't think the company can "hide" any longer, let alone in coming months, for annually, quarterly, and shareholder meeting, just a few quickly coming to mind;
yes, I am in line with Linda Powers in terms of getting it right, and for much bigger the prize at any means the law allows, and if it needs to take longer, so be it;
yes, I do think we are already derisked. Why lightening shares but not adding more?;
Thank God, I can see the primary endpoint be readily met, and patients will have a chance to live long term; for some cancer free for years to come. This is something the current SOC and FDA approved optune device cannot afford, and the very reason why RAs will and must approve it.
Yes I appreciate your sharing your encounter with DI on this board. Maybe next time you can share it timely so other retails who wants to lighten can lighten with you together.
GL to you for whatever you choose to do.
Regardless what you do, rambling, grudging, whining or pumping or just vicious attacks despite having no position long or short whatever;
Regardless how you read and analyze the data available to day about DCVax-L trial, the SOC, and the commercially available Optune device, and the conclusion you may draw from;
Regardless how you rate LP, and the management team, their strategy and what they have done today;
As least we all agree GMB is a deadest kind of cancer with unmet need in real life.
And the market agrees DCVax-L will get approved by four RAs by assigning a market cap of about $1.3 billion before TLD.
First step, confirm the market is right with positive tld of which it's almost certain the primary endpoint will be readily met with some unheard data showing long term survivals of three, four, five years.
Then, ten fold MC increase will be in the card (around $13 billion)for job well done and speculation of hefty revenue
Then, reasonable multiple will be given (up to $20 billion MC) considering other indications with now approved MOA.
In sequel or parallel, money will fly wilder and higher as DCVax-D comes to mind....
Not many retail investors will have the gut, wit and experience to hold for the big prize. They are born for pennies. I have seen this happening no end, and that's the nature of it.
When we see that accelerate we are real close regardless the term of in coming month or days or years. when it comes it arrives! Ladies and gentlemen, market is forward looking, it acts most times out of expectation!
Have I mentioned now I have been also adding shares to my wife accounts, about 100,000 now.
End of my rambling.
[Just realize this post is not intended in reply to RobotDroid. Sorry for that]
Newbies understanding of "in coming months":
= TLD announcement and/or publication spaced in days
My understanding and also those who have done their DD right:
= TLD, publication, an approval at least in UK spaced in days. And perhaps in between some other news such as partnership, or buyout chat/revelation (not just speculation)
There is no contradiction between Linda going alone and NWBIO being bought out with the news of manufacturing rapping up in UK, or elsewhere, the only difference is the suitor will have to pay more;
Technically and practically, Linda can go alone judged by things have been done so far.
You don't need a dedicated market team initially. The manufacturing may have a hard time to keep up!
As I said yesterday, the market yesterday was heavily and plainly manipulated to the news.
Maybe the recent acquisition of Cognate by CRL is the result of a tip-off that Cognate was preparing for FDA inspection just like Advent's which is in preparation for UK MHRA inspection soon.
Why in a hurry for an "overpriced" manufacturer?
NWBIO may be soon its predominant customer again.
Have a good evening (this is my last one for today)
this is actually what has been happening, confirmed by today's PR. MHAR would not inspect a manufacturing facility for readiness and then issue a certificate unless it has reviewed application/request or at least TLD
The same will be true for other RAs.
The market pretends otherwise today. It will change in due course.
Doc where have you been. I see Fudsters have succeeded somewhat in their FUD, now it seems that even you a long investor has had some doubt or uncertainty on whether TLD has been possessed/known by the company.
WOW, now I did see the use of those nonsense short narratives. When one reads them all, one may get drag along one day.
The reality is it has never been clearer from today's PR that the company has not only possessed TLD, but submitted/requested to UK MHRA for approval (probably FDA as well despite not explicitly indicated in this pr): the certification of manufacturing readiness is the last step for approval, which has never changed for any company who requests RA approval for its product, which usually comes after TLD, submission of NDA/BLA.
As far as price is concerned, it can be up and down on any news or no news for various reasons, depending on which one you pick, but any manipulation regardless of which way the price goes, it will settle down to the level commensurate to the true meaning of the news.
Today's news is super positive. It's just that the market fails to appropriately respond, as a result of manipulation.
I see steady price appreciation in the days ahead because partly of today's news (delayed effect just like immunotherapy LOL)
Come on what's the point to bring that pseudo "biotech" analyst up to life again on this board.
Not enough and useless already.
He has had nothing to offer, only being pull to act [by some body] behind the stage. You know that, don't you?
Not enough data to chew and gain enough confidence?
Save some energy to fight those Adams and plain village idiots who will soon come onboard again after Zoom meeting.
They are all on my ignore so I can only see them from you fighting them with your replying posts.
Charts are beautiful but only entertaining in small biotech land; the tailwind is the fundamental nobody can change.
You use a wrong word deceit. It's best for NWBIO to reveal as minimally as possible in a critically important period of time of approving the concept of DCVax for its first indication.
As you know the naked short wolfpack is relentless, evil and maybe capable as history has evidenced.
So why broadcast everything in planning or under development or trivial (compared with TLD or the ultimate success or failure, anything else may be deemed as trivial in my opinion). Instead only reveal information as legally required, such as the recent $11 million loan.
Any only reveal the information which has materialized or been accomplished. What's wrong with it?
Yes, the company has repeatedly moved its goal post, but at the time it did there must be enough reason of why it did so.
Things have been changing in multiple fronts in multiple ways we cannot staunchly ask the company to stubbornly stick to its goal as it requires adjustment, change when things change.
I feel comfortable despite impatience sometimes with how the company has been conducting its business, because I have basic trust in the company to take care of its investors, not focusing on the time being, but in a long term prospective.
Anytime I am impatient or weighing on whether buy more or not, I re-assess if the interests of the company (Linda's) are aligned with mine. So far I have not come out with a negative conclusion.
Maybe Linda gets a bigger piece of pie relative to mine but that's life I can accept.
when your goal is spelled out, there is only one hope/possibility; when you hide your goal (legally of course despite much grudge received), the possibilities are numerous!
In a shark infested waters, our journey will be clear and smooth with that kind of strategy.
If you still don't get it, better invest in other stocks where every moves will be broadcasted.
But, expect our strategy changes into the open, when we successfully accomplish our first journey.
I am willing to inject a little bit of fuel into our journey every now and then.
https://clincancerres.aacrjournals.org/content/27/1/11
CCR Perspectives in Regulatory Science and Policy
U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program
R. Angelo de Claro, Jennifer J. Gao, Tamy Kim, Paul G. Kluetz, Marc R. Theoret, Julia A. Beaver and Richard Pazdur
Add to Cart ($50)
DOI: 10.1158/1078-0432.CCR-20-2220 Published January 2021
Abstract
The FDA Oncology Center of Excellence commenced the Real-Time Oncology Review (RTOR) pilot project in February 2018 to facilitate earlier submission of topline results and datasets to support an earlier start to the FDA application review. RTOR was initially begun to support supplemental drug applications to add new indications, dosing regimens, or other clinical information to the prescribing information, but was later expanded to include original new drug applications and biological license applications for new molecular entities (NME). From February 2018 to April 2020, RTOR was used to support the submission and review of drug approvals for 20 oncology applications (11 for solid tumor and nine for hematologic malignancy indications). Two were NME drug approvals and 18 were supplemental approvals. All of the applications received priority review and nine (45%) applications had received breakthrough therapy designation status. FDA received the RTOR submissions a median of 5.7 weeks (range 1.7–16.2 weeks) prior to the full application submission. The median time from application submission to FDA approval was 3.3 months (range 0.4–5.9 months). RTOR was also integrated with other review programs including the Assessment Aid and Project Orbis programs. Innovative regulatory processes are critical to expedite the rigorous review of impactful products across the FDA.
Footnotes
Clin Cancer Res 2021;27:11–4
Received June 9, 2020.
Revision received July 20, 2020.
Accepted August 17, 2020.
Published first August 19, 2020.
©2020 American Association for Cancer Research.
This last post of mine for today is dedicated to the memory of those who have sold today after NWBIO secured about $11 million non-diluted loan four months after data lock on 5 October;
of those who had sold when blinded blended paper was published a few years ago, and subsequent uptrend OS data revealed; and
of those who had sold after German and UK revealed on their respective clinical trial registries the up-to-date revised, reordered endpoints.
What a short-sight, and what a pity!
of those who have dared or joyfully bought on those above events.
God blesses patients!
Exactly timung. Anyone at this point is still thinking we are waiting for a simple TLD is poor in normal brain function.
Yes TLD is pending, yes it will come out.
But, what we are actually waiting at this point is not a simple TLD and/or publication.
Don't need me to specify, and use your own brain function correctly ladies and gentlemen.
In other words, instead of waiting for a price hike one day to $3, we are waiting for a one day rocket up to $6.
Exactly, no sane person/entity would sign that kind of loan deal with a company whose pivotal phase 3 trial data was locked more than 4 long months ago without signing a NDA.
Yes one more evidence the trial is a success (I don't need this evidence anyhow as my previous multiple posts have revealed my confidence 100% based on data we have known so far about this trial and other failed trials as well as how SOC has panned out over decades)
The point as always is how successful the trial will be.
I think as least we will have 4 RA approval of DCVax-L for both nGBM and rGBM.
My last order for today as of now at 9:51am is much higher than yours at the current price of $1.33.
I will see what happen and may adjust my order if not filled.
Good luck
See you all tomorrow.
Bought 20k just now, and it's just starting for today.
At this price, even the weakest of Island boys would not convert any warrants or short any shares against their warrants. It's no action for them.
So the pathetic MMs or those funds who want to start a position or add more are playing with pathetic retail for a few share they can chip off.
In this sense, those MMs such as cdel and jane are just as pathetic as the pathetic retails.
Instead, to remove the pathetic hats from these MMs and funds's bald heads, they should stop acting now and the price will naturally appreciate.
Trust me, if price is a few dimes higher, they can get more shares in their coffers because there are more pathetic retail and island boys selling at "high" price than "low" price.
Men, I don't know why I am writing this since my buy orders have not been filled completely yet.
Hello $1.35 today, hello $10, $30... tomorrow (not literally of course)
Nothing in between but accumulation as many as you can afford. Please don't eat ramen noodles!
Primary endpoint will be readily met statistically significantly, so will at least some secondary endpoints if not all.
DCVax-L for GBM alone would grantee a share price in the range from $10-$30.
And it's just a fraction of the platform technology DCVax consisting of DCVax-L for all solid operable tumors and DCVax-D for all solid inoperable tumors.
Use a calculator and your brain to calculate whatever way you like, the numbers of potential share price is staggering, any numbers from $30 up is achievable.
Based on what we all know, DCVax-L trial for GBM is a success, which validates the MOA or the concept of DCVax platform.
All others are just FUDs.
Investing in accordance with your own DD man.
[btw, to be fair I need to talk about my investment: I have been net net increasing my investment and planned to do so until at least after the release of data, either tld, or more detail analysis. No time to constantly tear down anything speculative. Simply no time and not wise at the darkest time before dawn]
Exactly troc. It's one more sign built upon the general understanding or good practice that if the trial failed (I would deem a trial fails if it failed to meet its primary endpoint even later the underlying treatment could be approved from other strong indication), the company should have notified the general public.
Of course the blended blinded data says otherwise;
The revised reordered the endpoint suggests otherwise;
And even the current market cap, despite well undervalued, says otherwise.
GL.
Not correct. Below are primary and secondary endpoints according to Source: https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001977-13/GB
Please pay attention to the third secondary endpoint (PFS, is progression-free survival compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221), and the fourth secondary objective (OS, is overall survival compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.) these are the original primary and secondary endpoints!
"E.5 End points
E.5.1 Primary end point(s)
The primary endpoint of this study is overall survival (OS) compared between patients randomized to DCVax-L and control patients from comparable, contemporaneous trials who received standard of care therapy only, in patients with newly diagnosed glioblastoma.
E.5.1.1 Timepoint(s) of evaluation of this end point
October 2020
E.5.2 Secondary end point(s)
The first secondary endpoint is overall survival (OS) compared between patients randomized to placebo who received DCVax-L treatment following disease recurrence, and control patients from comparable, contemporaneous clinical trials, in patients with recurrent GBM.
The second secondary endpoint, confirmed progression-free survival (cPFS), is confirmed disease progression (cPD) compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.
The third secondary endpoint, PFS, is progression-free survival compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.
The fourth secondary objective, OS, is overall survival compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.
The fifth secondary objective is tumor response compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221."
The point is if topline data or unblinded data is known, are the parties in the know have the obligation to stop compassionate use (UK special program) in UK or anywhere it had been available before the know, if the data were bad or in other words, the data showed either not safe or not effective or both.
Although I have well past that psychological and scientific-based threshold, and just been wondering how success the data will be when it is revealed, there are always somebodies who would bring it about regardless the reasons behind.
In today's WS environment, almost all dead pigs (those stocks with prices stagnated for years) see their prices flying high regardless of fundamentals, we are siting in the narrow range of $1.5-$1.7, which makes me believe there have been indeed a great number of naked shorted shares still trapped.
And yes those few usual posters who claim having no shares/positions in NWBO but post 24/7 for years still glue in this board, repeating FUDs in hourly basis says yes they are trapped.
As Linda's friends, ie, those island boy financiers are diversifying their portfolios chasing any dead pigs they can find somewhere, we are patiently waiting. We will pass those boys who have no guts, vision and resources to buy in the open market to maintain a reasonable price, and enter a new investment world.
One of the dumbest things he has done, but he has had not other way out because the situation he faced at the time, is selling his vast holding of NWBO, if my memory can be relied upon, at around $0.19 a piece to Bigger C, etc.
The vultures always have meat in WS.
They are spoiled so no need to buy stocks in open market.
Was compelled to say a few words, maybe from drinking too much coffee this morning:
Avastin was approved by FDA in 2017 for rGBM patients for not improving OS but increased time to disease progression or death by about 2.7 months; [note it failed its primary endpoint of OS]
The current SOC for nGBM has not improved patient survivals for at least over a decade;
FDA approved Optune device for both n in 2015 and rGBM in 2011 has been controversial, but it doesn't prevent it from becoming a blockbuster treatment with market cap of about $19.5 billion today;
A great number of small developing stage biotech companies have seen their stock prices increased two to ten fold today from years of stalled prices in today's peculiar investment environment, despite many of these companies having no fundamental values at all but just stalled the price for a long time;
The 2018 JTM published DCVax-L data demonstrates both safety and efficacy of DCVax-L in treating nGBM. The following up data reveals an improved treatment trend;
The revised and reordered endpoints contained in the same revised SAP submitted to four RAs indicate the RAs have followed through with their understanding and updated guidance on the basis of the immunotherapy as a new class of cancer treatments which requires appropriate measurements for respective treatment efficiencies which are delayed but sustaining in nature;
From an educated guess and reasonable data analysis, the Phase 3 DCVax-L trial, datalocked as of 5 October, will be readily significant in meeting its primary endpoint, hence the investment in NWBO stock is no longer faced with a binary event.
And it can also be concluded from the above that it's highly likely the company has also been in negotiation with RAs for the approval of DCVax-L for rGBM besides the initial planned nGBM.
Since DCVax is a platform treatment for all solid tumors, if the price of DCVax-L for GMB indication is $10, then the price of NWBO by considering other indications shall readily reach multiple fold of the $10 as long as the concept of DCVax-L is approved.
Then, there will be the huge potential of DCVax-D coming into play.
The day of concept-of-approval unveiling DCVax-L trial data is quickly approaching!
I agree Swegen, but we have to take the first step before that.
The wall of $2, $3, $4, $5, $6, $7, $8, $9, $10, ... will fall as the platform is validated for the first indication of GBM.
We are so close to the major revelation. Besides what I said in my previous post, regarding our financiers, the so-called Linda's friendlies:
Despite having no guts and vision to buy shares in the open market so as to inject further confidence, hence better protect their own investment, they have mostly supported the grand scheme of Linda Powers of finally validating DCVax Platform for treating all solid tumors, by holding mostly their warrants/options not exercised.
But it seems these island boys and WS vultures have already de-risked enough, and gone into hibernation, by exercising and selling millions of warrants, selling shares against their warrants, etc.,
Plus one million verified shares increase in legal shorting scheme every two weeks, and disputed but trapped hundred of millions of naked short shares
that are some more signs we are really close to the serial of events we all have anticipated.
The dynamic shift is coming!
Reading your post I am actually relieved. Congratulations to you on your eventual figuring out how this management operates! Congratulations on your huge block on the ask!
This is exactly what I have anticipated what is going to happen as we are real close to huge revelation of the trial data in a unblinded way:
that retails would get enough of the bitter pill from waiting too long; new comers finally figured out how management is despising them, hence heading to exit;
that DI finally got enough, loosing temper telling some uneasy retails to shut up;
let alone the usual non-stop wolfpack nonsense! And the usual flip floppers is about to flip flop once again.
It must be close, really close!
Thank you Linda for holding your unswerving principles of not paying attention to retail nonsense, nuance, fuzziness, and instead focusing on the big picture, which in the end would benefit the true long much much more than that if the company is operated the usual way as some retails would like, for them making a dollar is a huge feast.
Pity those who still have not figured out how this management operates.
Too many signs pointing to success of not only a vaccine for GBM patients, but a paradigm shifting cancer immunotherapy platform for all solid tumors!
[be happy this company has been able to run as a private company so that Linda can be focused on the big picture!]
It's no longer a binary event. What it says to the price in the fine-tuned range of $ 1.5 ~ $1.7 or a market cap of around $1.3 billion:
Any shares below the price of $2 is a steal.
Just saying there are selling and there are buying. It's called market. Regardless what, either at price as high as $30 or as low as $0.14 there are always selling, and yes those sells are bought
So ladies and gentlemen, happy selling and buying as always
The difference is when fundamentals are confirmed for which many still fail to understand ever since the revised, reordered endpoints were revealed, the so-called binary event has long gone;
We are sensing now how successful the trial will be when TLD/detail data analyses are announced;
It has been a steady rise, despite in a slow pace, and this patter will soon be broken
It will be a rocket launch from the launch pad of $1.8 or $2
I am a buyer!
An advise from an animal science Full Professor, hope you have done well with your own money according to what you believe
My plain opinion is buy as many as you can afford at a price below $2
bye bye
Good luck to those who want to sell or threaten to sell
Good luck to those who bash hoping to get a position at a price as low as possible
Good luck to longs who have held for years, either adding more or holding steady
Karma to those who have ulterior agenda and bash day in and out 24/7 for years without having a position, long or short
In particular good luck to patients who are about to have an effective and extremely safe treatment, and for some a cure, of DCVax-L, with unprecedentedly solid, rich and long-term data in support
We are in a quiet period, a preparation for an explosive rise from a solid support of around $1.5 to $6 and beyond in in an instant any day now.
Yes any day, maybe 19 Feb, maybe today, and maybe 1 March
What the Fxx difference I see no
Thanks. If our financiers (the island boy club, the Bigger C, the thermo, and the like) can do just once a deal like this
Ocugen's stock triples on massive volume after institutional investors buy stock at a 27% premium
Published: Feb. 8, 2021 at 1:05 p.m. ET
By Tomi Kilgore
https://www.marketwatch.com/story/ocugens-stock-triples-on-massive-volume-after-institutional-investors-buy-stock-at-a-27-premium-2021-02-08
The market will say goodbye to $2 forever. No say they do it right now but the next deal if ever happens.
But they are all vulture in nature and lack of vision as I said repeatedly before so not really practical
While I agree with all what you said in your post, I do think confidence should be better injected through
Reading, studying and analyzing what we have learned about the current DCVax-L phase 3 trial for GBM patients, ie, the blinded, blended data published on
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6
and subsequent uptrending updates by Drs LL, Bosch;
the history, status and outcomes of the current standard of care, which indicates there has been almost no change in extending patients' survival both in terms of median or long term survival;
All previous phase 3 trials for GBM, and their respective results, the reasons why they all failed; and
Though despised by the majority of oncologists taking care of their GBM patients for its unclear MOA, difficult to use and added burden for already great hardship of their patients, the FDA approved Optune device has panned out quite well, illustrating the huge unmet demand. And if NWBIO updated its long-term survival data, Novocure would mysteriously come out with some cherry-picking if not outright faked data trying to have a match. All in all, if DCVax-L is approved its market cap shall double, triple the Novocure's which is currently at $19 billion.
It's pretty much certain DCVax-L trial will be significant in meeting its primary endpoint.
WE are siting at a price range of $1.5 ~ $1.7 for quite a time for a market cap of about $1.3 billion.
Some long term holders are trimming fat becoming lighter if not completely out of the game, new comers are mostly bashing (of course they want to initiate a position at a price as low as possible), and from time to time a tiny fraction of warrants gets dumped onto market. We are at a point now even nobody bothers to report their communications with DI or Les. The darkness seems to be upon us. How this situation can last.
I added about 100,000 shares in the last two weeks bringing my average up a bit
Good luck to you and all long
Too much nonsense as usual so I want to cut my post to the bone talking purely about buying, holding or selling nwbo for profit.
The status: today is more than 4 months after DL pr
For most small biotech companies they would have already pr tld, and yet we have not seen the tld pr yet because the company suggested they would announce tld and a publication in a closed by fashion.
A publication of detail data analysis according to Highwayman's link takes a year in average. However, NWBIO is not any way of that average company, and there are also examples of companies which take only a couple or a few months after DL for a publication for detail analysis.
For NWBIO
1) it's suggested NWBIO would release tld and publication almost simultaneously, unlike any average company which usually releases tld within two months of its DL pr, which takes the pressure off from publication (NWBIO is pressured for a quick publication from various fronts without announcing tld as soon as possible from DL pr);
2) NWBIO needs to raise funds for operations, and it cannot do that a) withholding tld/knowledge of trial results; and b) because it has run out of authorized shares.
As a result, NWBIO must pr tld at least in the near future if publication is still far away due purely to its financial needs. As a matter of fact, since it's already four months after DL pr, it's highly likely the publication may be about ready on any day ahead. Besides, the annual shareholder meeting is fast approaching, if prior years' experiences is a guide, we may be receiving notice on any day within this month. It's highly unlikely NWBIO would not reveal tld on or before the shareholder meeting.
Bottomline, from all we have known, it's quite probable DCVax-l P3 trial for GBM is significant in meeting its primary endpoint, and it's also quite probable it also meets some of its secondary endpoints. If DCVax-l is approved, it's very practical NWBIO would quickly achieve dominant market success/shares. A share price of $10 is readily achievable shortly after successful tld pr...
Conclusion:
No matter how patient you are or will be, the trial is most probably successful in meeting its major endpoints for nGBM, and it's an educated/studied speculation NWBIO may also seek approval of rGBM, which may explain at least in part for the existing long quiet period.
I don't know about you. Definitely as I have said several times in the past few months, I am a buyer, ie, net net my shares have steadily increased, bringing my average price steadily up.
For that I completely agree. That is why sometimes I rant, particularly on those island boy financiers, or the like such as Bigger C.
They lack of strong conviction, and are vulture in nature.
They are too passive no guts and too selfish and lack of vision
So no buy from open market.
But still it's totally out of our control, and at least I know what I am going to do
Not help man it's out of your control!
If they don't have the conviction and you have, let them sell and buy as much as you can afford at any opportunist time if any.
That's what I have done despite occasional rant.
In almost all the cases, old timers are thinner if not completely out of the game, new bloods come in in trough despite not yet so far, they will, as patience wears thin and dry, DI cannot catch up with new angry emails and phones
That's when it's time, not timed of course just my humble observation of more than two decades small biotech investment experience.
No complain today I am a buyer.
You have given very precise and succinct answers to the questions asked by the previous poster with a lot of critically important information. Thermo thank you.
I don't want to comment on each of your answer, but this particularly one, "She then compared the treatment arms in prior failed trials to the pooled ECD from the 5 trials. These trials failed when compared to internal SOC. These trials would also fail when compared to the ECD."
This should shut the fxxk months off of all the naked short wolfpack posters and elements present or not present in this board.
BTW, our treatment when compared to the internal SOC of the same pooled ECD from the 5 trials IMHO will be significant.
It suggests the treatment effect of DCVAx-L trial in GBM will be real, undeniable.
Can thermo's post be sticked?
You are welcome. I appreciate very much your support to the cause of what NWBIO has been in pursuit for over a decade!
NWBIO wins, we all win, let alone long suffering patients.
I think it's pathetic for you, a hedge fund manager/owner to promote other stock you have involved in financing in nwbo board. That says a lot about you. Of course other big names of nwbo financiers like bigger who had pounced when opportunity existed and never/almost never ever buy nwbo in the open market, and who know he might in effect have sold against his warrants.
You guys' shaky long thesis on nwbo is equally pathetic, or we would have seen some open market buy activities, or SEC reports, despite operated off the islands or something to that effect. By doing so [buying in the open market], you would protect your positions with appreciated share price and more market visibility
I have been in and out of otlk over the years, profitable but never ever has had the conviction I do in nwbo, a paradigm shifting cancer treatment platform.
Nothing wrong with what you are doing though, just cannot help.
Gap up today still in play!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161289177
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161292257
GAP UP TOMORROW